Publication:
Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers

dc.contributor.authorsCserni, G.; Wells, C. A.; Kaya, H.; Regitnig, P.; Sapino, A.; Floris, G.; Decker, T.; Foschini, M. P.; van Diest, P. J.; Grabau, D.; Reiner, A.; DeGaetano, J.; Chmielik, E.; Cordoba, A.; Andreu, X.; Zolota, V.; Charafe-Jauffret, E.; Ryska, A.; Varga, Z.; Weingertner, N.; Bellocq, J. P.; Liepniece-Karele, I.; Callagy, G.; Kulka, J.; Buerger, H.; Figueiredo, P.; Wesseling, J.; Amendoeira, I.; Faverly, D.; Quinn, C. M.; Bianchi, S.
dc.date.accessioned2022-03-12T20:30:29Z
dc.date.accessioned2026-01-11T17:20:00Z
dc.date.available2022-03-12T20:30:29Z
dc.date.issued2016
dc.description.abstractMicroinvasion is the smallest morphologically identifiable stage of invasion. Its presence and distinction from in situ carcinoma may have therapeutic implications, and clinical staging also requires the recognition of this phenomenon. Microinvasion is established on the basis of several morphological criteria, which may be difficult and not perfectly reproducible among pathologists. The aim of this study was to assess the consistency of diagnosing microinvasion in the breast on traditional haematoxylin and eosin (HE) stained slides and to evaluate whether immunohistochemistry (IHC) for myoepithelial markers could improve this. Digital images were generated from representative areas of 50 cases stained with HE and IHC for myoepithelial markers. Cases were specifically selected from the spectrum of in situ to microinvasive cancers. Twenty-eight dedicated breast pathologists assessed these cases at different magnifications through a web-based platform in two rounds: first HE only and after a washout period by both HE and IHC. Consistency in the recognition of microinvasion significantly improved with the use of IHC. Concordance rates increased from 0.85 to 0.96, kappa from 0.5 to 0.85, the number of cases with 100 % agreement rose from 9/50 to 25/50 with IHC and the certainty of diagnosis also increased. The use of IHC markedly improves the consistency of identifying microinvasion. This corroborates previous recommendations to use IHC for myoepithelial markers to clarify cases where uncertainty exists about the presence of microinvasion. Microinvasive carcinoma is a rare entity, and seeking a second opinion may avoid overdiagnosis.
dc.identifier.doi10.1007/s00428-016-1909-x
dc.identifier.eissn1432-2307
dc.identifier.issn0945-6317
dc.identifier.pubmed26818833
dc.identifier.urihttps://hdl.handle.net/11424/234179
dc.identifier.wosWOS:000374312900011
dc.language.isoeng
dc.publisherSPRINGER
dc.relation.ispartofVIRCHOWS ARCHIV
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectIn situ carcinoma
dc.subjectMicroinvasion
dc.subjectMyoepithelium
dc.subjectImmunohistochemistry
dc.subjectReproducibility
dc.subjectLYMPH-NODE BIOPSY
dc.subjectPHENOTYPIC ALTERATIONS
dc.subjectDUCTAL CARCINOMA
dc.subjectIN-SITU
dc.subjectCELLS
dc.subjectPATHOLOGY
dc.subjectLESIONS
dc.subjectCANCER
dc.subjectBENIGN
dc.titleConsistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage481
oaire.citation.issue4
oaire.citation.startPage473
oaire.citation.titleVIRCHOWS ARCHIV
oaire.citation.volume468

Files